Lung cancer
Conditions
Interventions
Experimental group:Intravenous esketamine infusion at 0.3 mg/kg/h during surgery. One vial of esketamine hydrochloride injection (50mg) is diluted with 0.9% normal saline to 50mL (concentration 1mg/mL
Control group:Intravenous infusion of an equal volume of 0.9% normal saline (50mL) during surgery. The infusion starts after tracheal intubation and stops at the end of surgery.
Sponsors
Tangdu Hospital, Air Force Medical University
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients scheduled for thoracoscopic lung cancer radical surgery under general anesthesia; 2. Age 45-60 years (menopausal women); 3. BMI 18-30 kg/m^2; 4. ASA physical status I-III; 5. Primary lung tumor without preoperative radiotherapy or chemotherapy; 6. Normal cognitive function; 7. Willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Refuse to participate in this study; 2. Communication disorders or inability to cooperate (e.g., language impairment, mental illness, epilepsy, Parkinson's disease); 3. Confirmed or suspected history of alcohol, analgesic or other drug abuse or addiction; 4. Allergy to esketamine; 5. Preoperative blood pressure >=180/110 mmHg; 6. Unstable angina or myocardial infarction within 3 months, or NYHA cardiac function grade =3; 7. Severe liver or kidney dysfunction; 8. Diabetic patients with diabetic complications; 9. COPD GOLD grade III-IV, pulmonary fibrosis, uncontrolled asthma; 10. History of lung surgery or conversion to thoracotomy; 11. Poor postoperative analgesia; 12. Patients with sleep disorders such as obstructive sleep apnea or restless legs syndrome; 13. Participation in other clinical trials within 3 months; 14. Other conditions deemed unsuitable for participation by the attending physician or investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative sleep disturbance on day 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative subjective sleep quality;Severity of postoperative insomnia;Postoperative anxiety and depression status;Postoperative pain score;Postoperative quality of recovery;Postoperative hospital stay;Incidence of postoperative adverse reactions;Total nocturnal sleep duration;Sleep efficiency;Daytime sleep duration;Nighttime awakening frequency;Deep sleep proportion;Light sleep proportion;REM sleep proportion;Pittsburgh Sleep Quality Index (PSQI);Estradiol (E2);Progesterone (P);Cortisol; | — |
Countries
China
Contacts
Public ContactLi Sun
Tangdu Hospital of the Fourth Military Medical University
Outcome results
None listed